StockData
Korsana Biosciences, Inc. logo

Korsana Biosciences, Inc. (KRSA) stock

KRSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30591% above fair value
$37.56+2.11 (+5.95%)

Close on Nov 20, 2026Market cap $175.83MP/E –Yield –

Korsana Biosciences free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Korsana Biosciences's free cash flow for the twelve months ending Dec 31, 2022 was -$40.61M. For fiscal 2022 it was -$40.61M. The highest annual figure on record is -$36.52M in fiscal 2021.

Annual free cash flow

PeriodPeriod endValueChange
FY2022Dec 31, 2022-$40.61M–
FY2021Dec 31, 2021-$36.52M–
FY2020Dec 31, 2020-$74.01M–
FY2019Dec 31, 2019-$109.10M–
FY2018Dec 31, 2018-$100.94M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$1.43M–
Q1 FY2026Mar 31, 2026-$1.24M–
Q2 FY2025Jun 30, 2025-$503.00K–
Q1 FY2025Mar 31, 2025-$968.00K–
Q4 FY2022Dec 31, 2022-$7.04M–
Q4 FY2021Dec 31, 2021-$8.63M–
Q4 FY2020Dec 31, 2020-$14.08M–
Q3 FY2020Sep 30, 2020-$15.06M–
Q2 FY2020Jun 30, 2020-$14.30M–
Q1 FY2020Mar 31, 2020-$30.59M–
Q4 FY2019Dec 31, 2019-$22.34M–
Q3 FY2019Sep 30, 2019-$24.47M–
Q2 FY2019Jun 30, 2019-$26.22M–
Q1 FY2019Mar 31, 2019-$36.09M–
Q4 FY2018Dec 31, 2018-$24.97M–
Q3 FY2018Sep 30, 2018-$26.46M–
Q2 FY2018Jun 30, 2018-$22.92M–
Q1 FY2018Mar 31, 2018-$26.59M–

More Korsana Biosciences figures

See a number that looks wrong?